$0.19
16.29% today
NYSE, Apr 03, 06:45 pm CET
ISIN
US14216R1014
Symbol
CARM
Sector
Industry

Carisma Therapeutics Stock price

$0.22
-0.18 44.51% 1M
-0.74 77.00% 6M
-0.20 46.94% YTD
-1.79 88.95% 1Y
-0.87 79.63% 3Y
-0.71 76.22% 5Y
-13.28 98.35% 10Y
NYSE, Closing price Wed, Apr 02 2025
-0.01 3.60%
ISIN
US14216R1014
Symbol
CARM
Sector
Industry

Key metrics

Market capitalization $9.29m
Enterprise Value $-6.14m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF 0.10
EV/Sales (TTM) EV/Sales -0.31
P/S ratio (TTM) P/S ratio 0.47
P/B ratio (TTM) P/B ratio negative
Revenue growth (TTM) Revenue growth 31.59%
Revenue (TTM) Revenue $19.63m
EBIT (operating result TTM) EBIT $-62.18m
Free Cash Flow (TTM) Free Cash Flow $-60.04m
Cash position $17.91m
EPS (TTM) EPS $-1.46
P/E forward negative
P/S forward 0.51
EV/Sales forward negative
Short interest 1.28%
Show more

Is Carisma Therapeutics a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,794 stocks worldwide.

Carisma Therapeutics Stock Analysis

Unlock Scores for Free

Analyst Opinions

4 Analysts have issued a Carisma Therapeutics forecast:

1x Buy
25%
3x Hold
75%

Analyst Opinions

4 Analysts have issued a Carisma Therapeutics forecast:

Buy
25%
Hold
75%

Financial data from Carisma Therapeutics

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Dec '24
+/-
%
20 20
32% 32%
100%
- Direct Costs 3.35 3.35
20% 20%
17%
16 16
52% 52%
83%
- Selling and Administrative Expenses 15 15
27% 27%
79%
- Research and Development Expense 60 60
20% 20%
304%
-59 -59
30% 30%
-300%
- Depreciation and Amortization 3.35 3.35
20% 20%
17%
EBIT (Operating Income) EBIT -62 -62
30% 30%
-317%
Net Profit -60 -60
30% 30%
-308%

In millions USD.

Don't miss a Thing! We will send you all news about Carisma Therapeutics directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Carisma Therapeutics Stock News

Neutral
PRNewsWire
3 days ago
Company to explore strategic alternatives to advance liver fibrosis and oncology assets and reduce operational cash burn PHILADELPHIA , March 31, 2025 /PRNewswire/ -- Carisma Therapeutics Inc. (Nasdaq: CARM) ("Carisma" or the "Company") today announced that its Board of Directors has approved a revised operating plan focused on evaluating strategic alternatives while reducing operational cash b...
Neutral
PRNewsWire
about one month ago
PHILADELPHIA , Feb. 19, 2025 /PRNewswire/ -- Carisma Therapeutics Inc. (Nasdaq: CARM) ("Carisma" or the "Company"), a leader in macrophage-focused therapeutics, today announced that Michael Klichinsky, PharmD, PhD, Co-founder and Chief Scientific Officer, will participate in the H.C. Wainwright 3rd Annual Cell Therapy Virtual Conference on Tuesday, February 25 at 10:30 am ET.
Neutral
PRNewsWire
about 2 months ago
PHILADELPHIA , Feb. 5, 2025 /PRNewswire/ -- Carisma Therapeutics Inc. (Nasdaq: CARM) ("Carisma" or the "Company"), a leader in macrophage-focused therapeutics, today announced that Steven Kelly, President and Chief Executive Officer, will participate in the Oppenheimer 35th Annual Healthcare Life Sciences Conference on Tuesday, February 11 at 4:40 pm ET. An audio webcast of the event will be av...
More Carisma Therapeutics News

Company Profile

Carisma Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the discovery and development of immunotherapies. It offers chimeric antigen receptor (CAR)-macrophages, a cell therapy platform focusing on the treatment of solid tumors. The company was founded by Michael Klichinsky and Saar Gill in 2016 and is headquartered in Philadelphia, PA.

Head office United States
CEO Steven Kelly
Employees 46
Founded 2016
Website carismatx.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today